Debilitating Pain and Fractures

A Rare Case of Hypophosphatemic Osteomalacia with Concomitant Vitamin D Deficiency in Neurofibromatosis Type 1

  • Shamharini Nagaratnam University Kebangsaan Malaysia Medical Centre (UKMMC)
  • Malathi Karupiah University Kebangsaan Malaysia Medical Centre (UKMMC)
  • Norlaila Mustafa University Kebangsaan Malaysia Medical Centre (UKMMC)
Keywords: NF1, hypophosphatemia, osteomalacia, FGF23, vitamin D deficiency

Abstract

Hypophosphatemic osteomalacia is a rare form of metabolic bone disorder in neurofibromatosis type 1 (NF1). The exact disease mechanism of this disorder in NF1 is yet to be established. We present a 44-year-old female known to have NF1, who presents with debilitating bone pain, weakness and multiple fractures. Laboratory investigations showed
persistent hypophosphatemia with renal phosphate wasting suggestive of hypophosphatemic osteomalacia. She also had concomitant vitamin D deficiency which contributed to the disease severity. Medical therapy with oral phosphate and vitamin D improved her symptoms without significant changes in fracture healing or phosphate levels.

Downloads

Download data is not yet available.

Author Biographies

Shamharini Nagaratnam, University Kebangsaan Malaysia Medical Centre (UKMMC)

Endocrine Fellow, Endocrine Unit, Department of Medicine

Malathi Karupiah, University Kebangsaan Malaysia Medical Centre (UKMMC)

Department of Medicine

 

Norlaila Mustafa, University Kebangsaan Malaysia Medical Centre (UKMMC)

Head of Department of Medicine,

Consultant Physician and Endocrinologist,

Endocrine Unit, Department of Medicine

References

Elefteriou F, Kolanczyk M, Schindeler A, Viskochil DH, Hock JM, Schorry EK, et al. Skeletal abnormalities in neurofibromatosis type 1: Approaches to therapeutic options. Am J Med Genet.

; 149A(1):2327–38. https://www.ncbi.nlm.nih.gov/pubmed/19764036. https://doi.org/10.1002/ajmg.a.33045.

Kumar S, Kushwaha P, Bharti N, et al. Elevated FGF23 in a patient with hypophosphatemic osteomalacia associated with neurofibromatosis type 1. Bone. 2019;129:115055. https://www.ncbi.nlm.nih.gov/pubmed/31476437. https://doi.org/10.1016/j.bone.2019.115055.

Gupta A, Dwivedi A, Patel P, Gupta S. Hypophosphatemic osteomalacia in von Recklinghausen neurofibromatosis: Case report and literature review. Indian J Radiol Imaging. 2015;25(1):63–6.

https://www.ncbi.nlm.nih.gov/pubmed/25709169. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329691.

https://doi.org/10.4103/0971-3026.150155.

Konishi K, Nakamura M, Yamakawa H, et al. Case report: Hypophosphatemic osteomalacia in Von Recklinghausen neurofibromatosis. Am J Med Sci.1991;301(5):322-8. https://www.ncbi.nlm.nih.gov/pubmed/1902351.

https://doi.org/10.1097/00000441-199105000-00006.

Abdel-Wanis M, Kawahara N. Hypophosphatemic osteomalacia in neurofibromatosis 1: Hypotheses for pathogenesis and higher incidence of spinal deformity. 2002;59(2):183–5. https://www.ncbi.nlm.nih.gov/pubmed/12208207. https://doi.org/10.1016/s0306-9877(02)00254-2.

Michigami T. Skeletal mineralization : Mechanisms and diseases. Ann Pediatr Endocrinol Metab. 2019;24(4):213-9. https://www.ncbi.nlm.nih.gov/pubmed/31905439. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944863. https://doi.org/10.6065/apem.2019.24.4.213.

Jagtap VS, Sarathi V, Lila AR, Bandgar T, Menon P, Shah NS. Hypophosphatemic rickets. India J Endocrinol Metab.2012;16(2):177-82. https://www.ncbi.nlm.nih.gov/pubmed/22470852. https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC3313733.

https://doi.org/10.4103/2230-8210.93733.

Collins MT, Hartley IR, Florenzano P. Tumor-induced osteomalacia. Principles of Bone Biology. Elsevier Inc.; 2020. Targeted disruption of NF1 in osteocytes increases FGF23 and osteoid with osteomalacia-like bone phenotype. J Bone Miner Res. 2017;32(8):1716-26.

https://www.ncbi.nlm.nih.gov/pubmed/28425622. https://doi.org/10.1002/jbmr.3155.

Insogna KL, Briot K, Imel EA, et al. A Randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with x-linked hypophosphatemia: Week 24 primary analysis. J Bone Miner Res. 2018;33(8):1383-93.

https://www.ncbi.nlm.nih.gov/pubmed/29947083. https://doi.org/10.1002/jbmr.3475.

Imel EA, Glorieux FH, Whyte MP, et al. Burosumab versus conventional therapy in children with x-linked hypophosphataemia: A randomised, active-controlled, open-label, phase 3 trial.

Lancet. 2019;393(10189):2416-27. https://www.ncbi.nlm.nih.gov/pubmed/31104833. https://doi.org/10.1016/S0140-6736(19)30654-3.

Jan De Beur S, Miller P, Weber T, et al. OR13-1 Burosumab improves the biochemical, skeletal, and clinical symptoms of tumor-induced osteomalacia syndrome. J Endocr Soc . 2019;3(Suppl 1):

OR13. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554835. https://doi.org/10.1210/js.2019-OR13-1.

Published
2020-04-20
How to Cite
Nagaratnam, S., Karupiah, M., & Mustafa, N. (2020). Debilitating Pain and Fractures: A Rare Case of Hypophosphatemic Osteomalacia with Concomitant Vitamin D Deficiency in Neurofibromatosis Type 1. Journal of the ASEAN Federation of Endocrine Societies, 35(1). Retrieved from https://asean-endocrinejournal.org/index.php/JAFES/article/view/757